| Aug 21 |
aTyr Pharma to Participate in September Investor Conferences
|
| Aug 15 |
Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth?
|
| Aug 13 |
aTyr Pharma GAAP EPS of -$0.23 beats by $0.01
|
| Aug 13 |
aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update
|
| Aug 6 |
aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations
|
| Jul 30 |
aTyr Pharma Announces Research Study with Stanford Medicine
|
| Jul 26 |
Independent Director of aTyr Pharma Paul Schimmel Buys 10.0% More Shares
|
| Jul 25 |
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
|
| Jul 22 |
aTyr Pharma Completes Enrollment in Global Pivotal Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
|
| Jul 12 |
aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company
|
